Featured Story

  • Amarantus, Anavex team up for Alzheimer's biomarker Dx

    Amarantus BioSciences Holdings struck a deal with Anavex Life Sciences to provide biomarker test services for the company's Alzheimer's drug candidates, a major win for Amarantus as it looks to expand the reach of its blood-based diagnostic test.

Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx

Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.

Vigilant Biosciences reels in $5.5M for oral cancer test

Vigilant Biosciences roped in $5.5 million in a Series B round to support development of its diagnostic system for the early detection of oral cancer, giving the company a boost as it eyes European and stateside approval for its product.

Israeli colon capsule maker reels in $24M in IPO and private placement

Israeli diagnostic outfit Check-Cap raised $24 million in an initial public offering and a simultaneous private placement, giving the company a boost as it looks to develop its disposable imaging capsules for colorectal cancer screening.

Department of Defense gives contractor $14.8M to test so-called Sample-to-Sequence system

The Department of Defense has a habit of funding new medical technologies. This week it awarded a government contractor MRIGlobal $14.8 million for its proposed Sample-to-Sequence system to sequence the entire genome of pathogens and give a diagnosis within 24 hours.

Roche, BioMed X to jointly run diagnostics incubator in Germany

Roche and BioMed X are teaming up to create a diagnostics research group focused on biosensors and nanomaterials such as graphene within BioMed X's open innovation lab in Heidelberg, Germany. 


From Our Sister Sites


Petaluma, CA-based Oculus Innovative Sciences announced Thursday that it has launched an animal health unit and 6 new products for the treatment of wounds, skin and eyes.


St. Jude Medical agreed to pay as much as $14.25 million to settle about 950 claims related to its Riata defibrillator leads. The wires used to shock a heart that is beating abnormally degraded in as few as four years and were pulled from the market in 2010.